Xeris’ severe low blood sugar pen gets FDA approvalAfter 14 years of operations Xeris Pharma has its first-ever product approval, claiming an FDA okay for a Share XXeris’ severe low blood sugar pen gets FDA approvalhttps://pharmaphorum.com/news/xeris-severe-low-blood-sugar-pen-gets-fda-approval/
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trialEli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for Share XRelief for Lilly as drug from $8bn Loxo deal clears pivotal trialhttps://pharmaphorum.com/news/relief-for-lilly-as-drug-from-8bn-loxo-deal-clears-pivotal-trial/
Mylan up on OK for generic of Lilly’s $2bn cancer drug AlimtaShares in Mylan have risen after the FDA gave a tentative approval to its generic version of Eli Share XMylan up on OK for generic of Lilly’s $2bn cancer drug Alimtahttps://pharmaphorum.com/news/mylan-up-on-ok-for-generic-of-lillys-2bn-cancer-drug-alimta/
Eli Lilly launches inflammatory bowel disease digital challengeEli Lilly is launching a challenge encouraging individuals and teams across the US to develop digital health solutions Share XEli Lilly launches inflammatory bowel disease digital challengehttps://pharmaphorum.com/news/eli-lilly-launches-inflammatory-bowel-disease-digital-challenge/
Roche’s CMO Horning to retire, Lilly’s high-flyer Garraway steps inRoche’s influential chief medical officer Sandra Horning is to retire at the end of the year, the company Share XRoche’s CMO Horning to retire, Lilly’s high-flyer Garraway steps inhttps://pharmaphorum.com/news/roches-cmo-horning-to-retire/
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in EuropeTwo biosimilars of Eli Lilly’s blockbuster osteoporosis treatment Forsteo – from Hungary’s Gedeon Richter and German partner Stada Share XLilly faces biosimilar rivals to osteoporosis drug Forsteo in Europehttps://pharmaphorum.com/news/lilly-faces-biosimilar-rivals-to-osteoporosis-drug-forsteo-in-europe/
2nd RNA Targeted Drug Discovery SummitAt a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Share X2nd RNA Targeted Drug Discovery Summithttps://pharmaphorum.com/events/2nd-rna-targeted-drug-discovery-summit/
Lilly firms up case for Emgality in migraine market chaseEli Lilly’s third-to-market migraine prevention drug Emgality has a lot of ground to make up on its rivals, Share XLilly firms up case for Emgality in migraine market chasehttps://pharmaphorum.com/news/lilly-firms-up-case-for-emgality-in-migraine-market-chase/
Lilly dips as biomed chief Christi Shaw heads to GileadChristi Shaw, president of Eli Lilly Bio-Medicines is leaving the company after two years, taking the top job Share XLilly dips as biomed chief Christi Shaw heads to Gileadhttps://pharmaphorum.com/news/lilly-dips-as-biomed-chief-christi-shaw-heads-to-gilead/
